187 related articles for article (PubMed ID: 16514710)
21. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; Mahon FX
Br J Haematol; 2002 Oct; 119(1):109-11. PubMed ID: 12358910
[TBL] [Abstract][Full Text] [Related]
22. [Roles of the 2nd generation TKIs for CML].
Matsumura I
Rinsho Ketsueki; 2011 Oct; 52(10):1610-8. PubMed ID: 21971238
[No Abstract] [Full Text] [Related]
23. A case with coexistence of major and minor BCR/ABL fusion transcript at lymphoblastic crisis of chronic myelogenous leukemia in patients with major BCR/ABL positivity during chronic phase.
Park SH; Chi HS; Cho YU; Jang S; Park CJ; Im HJ
Ann Lab Med; 2013 Jan; 33(1):80-3. PubMed ID: 23301228
[No Abstract] [Full Text] [Related]
24. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
Parmar KK; King RS
Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
[No Abstract] [Full Text] [Related]
25. Activity of AMN107 in gleevec-resistant leukemia.
Cancer Biol Ther; 2006 Jan; 5(1):8. PubMed ID: 16924763
[No Abstract] [Full Text] [Related]
26. Precipitation of porphyria cutanea tarda by imatinib mesylate?
Ho AY; Deacon A; Osborne G; Mufti GJ
Br J Haematol; 2003 Apr; 121(2):375. PubMed ID: 12694262
[No Abstract] [Full Text] [Related]
27. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
Mattison R; Larson RA
Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
[No Abstract] [Full Text] [Related]
28. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
29. Imatinib (Gleevec) as a paradigm of targeted cancer therapies.
Druker B
Keio J Med; 2010; 59(1):1-3. PubMed ID: 20375651
[No Abstract] [Full Text] [Related]
30. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
31. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J
Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059
[TBL] [Abstract][Full Text] [Related]
32. Improving the management of chronic myeloid leukaemia.
Neylon A; O'Brien S
Hosp Med; 2001 Sep; 62(9):553-5. PubMed ID: 11584615
[TBL] [Abstract][Full Text] [Related]
33. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
34. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
35. A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.
Park MJ; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Jeong JW; Ahn JY; Park J
Ann Lab Med; 2014 May; 34(3):247-51. PubMed ID: 24790915
[No Abstract] [Full Text] [Related]
36. Cancer in the crosshairs.
Martindale D
Sci Am; 2001 Sep; 285(3):19-20. PubMed ID: 11524965
[No Abstract] [Full Text] [Related]
37. Bcr-Abl inhibition as a modality of CML therapeutics.
Buchdunger E; Matter A; Druker BJ
Biochim Biophys Acta; 2001 Aug; 1551(1):M11-8. PubMed ID: 11553417
[No Abstract] [Full Text] [Related]
38. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
Yeung DT; White DL
Leuk Lymphoma; 2011 Feb; 52(2):165-7. PubMed ID: 21171867
[No Abstract] [Full Text] [Related]
39. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
40. Glivec and beyond.
Eur J Cancer; 2006 Aug; 42(12):1695. PubMed ID: 16998957
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
